AI assistant
Mankind Pharma Limited — Call Transcript 2024
Jan 19, 2024
61869_rns_2024-01-19_f58a00e6-ed45-46a2-9fae-6f76020f6b85.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [594 x 114] intentionally omitted <==
Date: January 19, 2024
BSE Limited P J Towers, Dalal Street, Mumbai – 400 001
Script Code: 543904
National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Symbol: MANKIND
Dear Sir/ Madam,
Subject: Intimation of Investor Conference Call for Q3 FY24 with Senior Management of Mankind Pharma Limited (“the Company”)
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will host Investor Conference Call on Friday, February 2, 2024 at 12:00 noon (IST) for Q3 FY24.
Details of the Investor Conference Call are enclosed herewith.
The same are also being uploaded on website of the Company at www.mankindpharma.com.
You are requested to kindly take the same on records.
Thanking You,
Yours Faithfully,
For Mankind Pharma Limited
PRADEEP Digitally signed by PRADEEP CHUGH CHUGH Date: 2024.01.19 18:55:06 +05'30' Pradeep Chugh Company Secretary and Compliance Officer Membership No. A18711
==> picture [590 x 64] intentionally omitted <==
==> picture [148 x 95] intentionally omitted <==
Mankind Pharma Limited Earnings Call Invite | Q3 & 9M FY24
You are cordially invited to the Earnings Call, Scheduled on Friday, 2[nd] February 2024, at 12:00 Noon IST , To discuss Q3 & 9M FY24 business performance and results:
The details of the earnings call are as below:
| Earnings Call Details | Earnings Call Details |
|---|---|
| Date | 2ndFebruary 2024 |
| Time | 12:00 Noon - 01:00 PM, IST |
| Universal Dial-in | +91 22 6280 1102+91 22 7115 8003 |
| International Toll-Free Numbers | USA:18667462133UK:08081011573Singapore:8001012045Hong Kong:800964448 |
| Pre-register to avoid wait time | Click here to pre-register for the call and dial in directlywithout waiting for the operator. |
Management will be represented by:
-
Mr. Rajeev Juneja – Vice Chairman & Managing Director
-
Mr. Sheetal Arora – Chief Executive Officer & Whole Time Director
-
Mr. Arjun Juneja - Chief Operating Officer
-
Dr. Sanjay Koul – Chief Marketing Officer
-
Mr. Ashutosh Dhawan – Chief Financial Officer
-
Mr. Prakash Agarwal – President (Strategy)
-
Mr. Abhishek Agarwal – Head (Investor Relations)
For details, please contact:
| Mankind Pharma LimitedAbhishek AgarwalInvestor RelationsE:[email protected],T: 011 – 46846700,Ext: 3532 | Adfactors PRSnighter Albuquerque / Smit ShahE:[email protected]/[email protected], M: +91 9870789596 |
|---|